INVESTMENT COMPONENT OF TRANSNATIONALIZATION DURING COVID-19 PANDEMIC ON THE EXAMPLE OF INTERNATIONAL CORPORATIONS

Authors

  • A.V. Shapoval Odessa I. I. Mechnikov National University, Department of World Economy and International Economic Relations, 2 Dvoryanska str., Odessa, 65082 https://orcid.org/0000-0003-4100-2013
  • S.O. Yakubovskiy Odessa I. I. Mechnikov National University, Department of World Economy and International Economic Relations, 2 Dvoryanska str., Odessa, 65082 https://orcid.org/0000-0002-1193-0241

DOI:

https://doi.org/10.15330/apred.1.18.147-157

Keywords:

pharmaceutical corporations, investment, R&D, pandemic impact

Abstract

The article analyzes the general situation of transnationalization over several years highlights the changes at the beginning of the pandemic caused by the spread of Covid-19. It has been established that oscillatory investment dynamics characterize the period from 1990 to 2020 flows at the global level. The impact of global problems on the activities of corporations in 2020 is noted. The main external factors influencing the activities of the investment nature of corporations in this period are the consequences of the coronavirus infection. According to statistics, a significant drop in investment flows in 2020 was presented, but thanks to the activities of transnational corporations in the fight against the global pandemic, an improvement in the situation were predicted in subsequent years. Pharmaceutical corporations have been identified as the leading players in the fight against the pandemic among TNCs due to significant involvement and cooperation with governments, society, and businesses, both at the national and international levels. As a result, pharmaceutical multinationals resumed their presence in the ranking of innovative companies in 2021 in terms of investment in R&D, significantly improving their positions compared to previous years. With the help of a regression model, using the example of a pharmaceutical company, the dependence of a corporation's income on investment in research and development was demonstrated. At the same time, statistical, graphical and comparative analyzes were used in the article.

The article analyzes structural changes in R&D investment companies to understand the reorientation of activities. The reorientation in international companies has made it possible to assert the pandemic as a strategic opportunity to develop new products by pharmaceutical companies directly related to the fight against coronavirus infection, the creation of cooperation between companies of different levels, and a change in segmentation in the product line. Furthermore, a timely response to the challenges of the pandemic and a change in tactics allowed pharmaceutical companies to stay afloat and improve their financial performance, and the situation with investment flows in general.

 

Author Biographies

A.V. Shapoval , Odessa I. I. Mechnikov National University, Department of World Economy and International Economic Relations, 2 Dvoryanska str., Odessa, 65082

postgraduate

S.O. Yakubovskiy , Odessa I. I. Mechnikov National University, Department of World Economy and International Economic Relations, 2 Dvoryanska str., Odessa, 65082

Doctor of Economics, Professor

References

1. Higon D.A., and M.M. Antolin. “Multinationality, foreignness and institutional distance in the relation between R&D and productivity”. Research Policy, vol. 41 (3), 2012, pp. 592-601.
2. Dominese G., and T. Rodionova, A. Shapoval, S. Yakubovskiy. “Impact of transnational corporations activity on the economic development of Ukraine”. Transition Studies Review, vol. 28 (1), 2021, pp. 121–134.
3. Shapoval A., and S. Yakubovskiy. “R&D as a basis for the growth of multinational enterprises”. Multinational enterprises and the global economy. Monograph, 2020, pp. 167 – 185.
4. Yakubovskiy S. A., and K.S. Yugay. “Modern Dominants of the Transnationalization of International”. Business Bulletin of Odessa National University. Series: Economics, in 23 vol., vol. 1 (66), pp. 12-16.
5. VanderPal G.A. “Impact of R&D Expenses and Corporate Financial Performance”. Journal of Accounting and Finance, vol. 15 (7), 2017, pp. 135-149.
6. Statistical data, World Bank Open Data, 2021, https://data.worldbank.org. Accessed 29 Sept. 2021.
7. World Investment Report 2021: Investing in Sustainable Recovery, UNCTAD, 2021, https://unctad.org/system/files/official-document/wir2021_en.pdf. Accessed 29 Sept. 2021.
8. Statistical data, World Trade Organization, 2021, https://www.wto.org/english/news_e/pres21_e/pr876_e.htm. Accessed 29 Sept. 2021.
9. Reports: The most Innovative Companies, Boston Consulting Group., 2021, https://www.bcg.com/publications/most-innovative-companies-historical-rankings. Accessed 30 Sept. 2021.
10. News Archive 2020, Novartis Corporation, https://www.novartis.com/news/news-archive. Accessed 1 Oct. 2021.
11. Annual reports 2020, Johnson & Johnson, 2021, https://www.jnj.com/about-jnj/annual-reports. Accessed 1 Oct. 2021.
12. Annual report 2020, Bayer, 2021, https://www.bayer.com/en/media/integrated-annual-reports. Accessed 1 Oct. 2021.
13. News Archive 2020, Arvinas, https://ir.arvinas.com. Accessed 1 Oct. 2021.
14. Press Release, CureVac N.V., 2021, https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/. Accessed 1 Oct. 2021.
15. Annual reports 2020, Phillips N.V., 2021, https://www.results.philips.com/publications/ar20. Accessed 1 Oct. 2021.
16. Annual reports 2020, Pfizer Inc., 2021, https://investors.pfizer.com/financials/annual-reports/default.aspx. Accessed 1 Oct. 2021.
17. Annual report 2020, BioNTech SE, 2021, https://investors.biontech.de/annual-reports/. Accessed 1 Oct. 2021.

Downloads

Published

2022-06-26

Issue

Vol. 1 No. 18 (2022): THE ACTUAL PROBLEMS OF REGIONAL ECONOMY DEVELOPMENT

Section

International economic relations

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution NonCommercial NoDerivs 4.0 Unported License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)